115 related articles for article (PubMed ID: 27566181)
1. Adenovirus-mediated shRNA interference against HSV-1 replication in vitro.
Song B; Liu X; Wang Q; Zhang R; Yang T; Han Z; Xu Y
J Neurovirol; 2016 Dec; 22(6):799-807. PubMed ID: 27566181
[TBL] [Abstract][Full Text] [Related]
2. Multi-targeted gene silencing strategies inhibit replication of Canine morbillivirus.
de Carvalho OV; Rebouças Santos M; Lopes Rangel Fietto J; Pires Moraes M; de Almeida MR; Costa Bressan G; José Pena L; Silva-Júnior A
BMC Vet Res; 2020 Nov; 16(1):448. PubMed ID: 33213424
[TBL] [Abstract][Full Text] [Related]
3. Herpes simplex virus type 1 cleavage and packaging proteins UL15 and UL28 are associated with B but not C capsids during packaging.
Yu D; Weller SK
J Virol; 1998 Sep; 72(9):7428-39. PubMed ID: 9696839
[TBL] [Abstract][Full Text] [Related]
4. Recruitment of cellular recombination and repair proteins to sites of herpes simplex virus type 1 DNA replication is dependent on the composition of viral proteins within prereplicative sites and correlates with the induction of the DNA damage response.
Wilkinson DE; Weller SK
J Virol; 2004 May; 78(9):4783-96. PubMed ID: 15078960
[TBL] [Abstract][Full Text] [Related]
5. Lentivirus expressing shRNAs inhibit the replication of contagious ecthyma virus by targeting DNA polymerase gene.
Asadi Samani L; Saffar B; Mokhtari A; Arefian E
BMC Biotechnol; 2020 Mar; 20(1):18. PubMed ID: 32293394
[TBL] [Abstract][Full Text] [Related]
6. Combinatorial RNAi against HIV-1 using extended short hairpin RNAs.
Liu YP; von Eije KJ; Schopman NC; Westerink JT; ter Brake O; Haasnoot J; Berkhout B
Mol Ther; 2009 Oct; 17(10):1712-23. PubMed ID: 19672247
[TBL] [Abstract][Full Text] [Related]
7. MYBBP1A is required for efficient replication and gene expression of herpes simplex virus 1.
Nobe M; Maruzuru Y; Takeshima K; Koyanagi N; Kato A; Kawaguchi Y
Microbiol Immunol; 2024 Apr; 68(4):148-154. PubMed ID: 38402407
[TBL] [Abstract][Full Text] [Related]
8. The impact of unprotected T cells in RNAi-based gene therapy for HIV-AIDS.
Herrera-Carrillo E; Liu YP; Berkhout B
Mol Ther; 2014 Mar; 22(3):596-606. PubMed ID: 24336172
[TBL] [Abstract][Full Text] [Related]
9. Stable expression of shRNA for the control of recombinant adenovirus replication.
Lana MVG; Antunes F; Tessarollo NG; Strauss BE
Braz J Med Biol Res; 2023; 56():e12682. PubMed ID: 37493770
[TBL] [Abstract][Full Text] [Related]
10. Anticipating and blocking HIV-1 escape by second generation antiviral shRNAs.
Schopman NC; ter Brake O; Berkhout B
Retrovirology; 2010 Jun; 7():52. PubMed ID: 20529316
[TBL] [Abstract][Full Text] [Related]
11. The herpes simplex virus type 1 UL3 transcript starts within the UL3 open reading frame and encodes a 224-amino-acid protein.
Markovitz NS
J Virol; 2007 Oct; 81(19):10524-31. PubMed ID: 17626086
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of viruses by RNA interference.
Stram Y; Kuzntzova L
Virus Genes; 2006 Jun; 32(3):299-306. PubMed ID: 16732482
[TBL] [Abstract][Full Text] [Related]
13. 96 shRNAs designed for maximal coverage of HIV-1 variants.
McIntyre GJ; Groneman JL; Yu YH; Jaramillo A; Shen S; Applegate TL
Retrovirology; 2009 Jun; 6():55. PubMed ID: 19497094
[TBL] [Abstract][Full Text] [Related]
14. Multiplexing seven miRNA-Based shRNAs to suppress HIV replication.
Choi JG; Bharaj P; Abraham S; Ma H; Yi G; Ye C; Dang Y; Manjunath N; Wu H; Shankar P
Mol Ther; 2015 Feb; 23(2):310-20. PubMed ID: 25358251
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Tulane virus replication in vitro with RNA interference.
Fan Q; Wei C; Xia M; Jiang X
J Med Virol; 2013 Jan; 85(1):179-86. PubMed ID: 23154881
[TBL] [Abstract][Full Text] [Related]
16. Augmented antiviral activity of chlorhexidine gluconate on herpes simplex virus type 1, H1N1 influenza A virus, and adenovirus in combination with salicylic acid.
Jamshidinia N; Saadatpour F; Arefian E; Mohammadipanah F
Arch Virol; 2023 Nov; 168(12):302. PubMed ID: 38036721
[TBL] [Abstract][Full Text] [Related]
17. CRISPR/Cas-9 vector system: targets UL-39 and inhibits Simplexvirus humanalpha1 (HSV-1) replication in vitro.
Vasques Raposo J; Rodrigues Carvalho Barros L; Ribas Torres L; Barbosa da Silva Pinto R; De Oliveira Lopes A; Mello de Souza E; Hernan Bonamino M; Salete de Paula V
Cell Mol Biol (Noisy-le-grand); 2023 Jul; 69(7):19-23. PubMed ID: 37715442
[TBL] [Abstract][Full Text] [Related]
18. RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA?
Subramanya S; Kim SS; Manjunath N; Shankar P
Expert Opin Biol Ther; 2010 Feb; 10(2):201-13. PubMed ID: 20088715
[TBL] [Abstract][Full Text] [Related]
19. RNAi-mediated inhibition of HIV-1 by targeting partially complementary viral sequences.
Liu YP; Gruber J; Haasnoot J; Konstantinova P; Berkhout B
Nucleic Acids Res; 2009 Oct; 37(18):6194-204. PubMed ID: 19656954
[TBL] [Abstract][Full Text] [Related]
20. In silico modeling indicates the development of HIV-1 resistance to multiple shRNA gene therapy differs to standard antiretroviral therapy.
Applegate TL; Birkett DJ; Mcintyre GJ; Jaramillo AB; Symonds G; Murray JM
Retrovirology; 2010 Oct; 7():83. PubMed ID: 20932334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
